These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8453962)

  • 1. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1993; 44(2):171-6. PubMed ID: 8453962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1988; 34(4):395-400. PubMed ID: 3402525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
    Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
    Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.
    Brunner L; Imhof P; Jack D
    Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different preparations of oxprenolol on diurnal variations of non-steady-state exercise performance in patients with coronary heart disease evaluated by computer assisted ergospirometry.
    Reiterer W
    Arzneimittelforschung; 1980; 30(7):1147-53. PubMed ID: 7191298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oxprenolol in normal subjects.
    Mason WD; Winer N
    Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
    van Baak MA; Verstappen FT; Oosterhuis B
    Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic studies in man of the beta-adrenoceptor antagonist DL 071 IT.
    Radice M; Amanzio R; Criscuolo D
    Eur J Clin Pharmacol; 1979 Sep; 16(2):87-90. PubMed ID: 40801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of oxprenolol alone and combined with nitroglycerin in patients with ischemic heart disease.
    Lecerof H; Malmborg RO
    Acta Med Scand; 1972 Dec; 192(6):499-506. PubMed ID: 4629694
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemodynamic effects and variations in plasma renin activity after single oral administration of oxprenolol.
    Kuramoto K; Kurihara H; Murata K; Kimata S; Matsushita S
    Cardiology; 1974; 59(1):41-8. PubMed ID: 4419013
    [No Abstract]   [Full Text] [Related]  

  • 18. Haemodynamic dose-response effects of intravenous oxprenolol in coronary heart disease.
    Silke B; Hilal A; Taylor SH
    J Cardiovasc Pharmacol; 1981; 3(4):716-27. PubMed ID: 6167802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.
    Barritt DW; Marshall AJ; Heaton S
    Lancet; 1976 Mar; 1(7958):503-5. PubMed ID: 55780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and dynamics of oxprenolol: a simulation study with six subjects.
    Saunders L; Ingram D; Warrington SJ
    J Pharm Pharmacol; 1985 Nov; 37(11):802-6. PubMed ID: 2867161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.